This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
TMDX Stock Down Despite Responding to Misleading Short-Seller Report
by Zacks Equity Research
TransMedics addresses the misleading claims made in a short-seller report issued by Scorpion Capital.
TCMD Stock Rises 20% in Three Months: Should You Buy, Hold or Sell?
by Indrajit Bandyopadhyay
Tactile Systems' top line reflects strong demand for its existing products. Workflow enhancements are driving efficiency. Rising Medicare documentation requirements are a headwind.
TransMedics Stock Plunges 57.5% in Three Months: What's Next?
by Debanjana Dey
TMDX is enhancing its current focus on making meaningful progress across each of its growth initiatives. However, macro challenges are likely to hurt its performance.
Is TMDX Stock a Buy, Sell or Hold at a P/S Multiple of 5.02X?
by Indrajit Bandyopadhyay
TransMedics is facing a softness in demand for transplant services in the United States. Moreover, rising costs raise concern.
TransMedics (TMDX) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for TransMedics (TMDX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
TransMedics Stock Falls as Q3 Earnings & Sales Miss Estimates
by Zacks Equity Research
TMDX's third-quarter revenues increase with the utilization of the OCS across all three organs and additional revenues generated by its logistics services. Gross margin contracts.
TransMedics (TMDX) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of -57.14% and 4.78%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
IQVIA Holdings (IQV) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stay Ahead of the Game With TransMedics (TMDX) Q3 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Evaluate the expected performance of TransMedics (TMDX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Transplant Logistic Service Business Likely to Aid TMDX's Q3 Earnings
by Zacks Equity Research
Expanding transplant logistic service business is likely to have driven TransMedics' third-quarter 2024 performance.
HSIC Gears Up for Q3 Earnings: Here's What You Need to Know
by Zacks Equity Research
Henry Schein is expected to report impressive sales in both its businesses in the third quarter of 2024, along with a low pace of recovery from the cyber incident.
Will Screening Sales Drive Exact Sciences' Q3 Earnings?
by Zacks Equity Research
Precision Oncology revenues of EXAS are likely to have been boosted by laboratory service revenues from global Oncotype DX and therapy selection tests.
CRL Gears Up for Q3 Earnings: Here's What You Need to Know
by Zacks Equity Research
Growth across all businesses within the Manufacturing segment is likely to have contributed to Charles River's Q3 revenues, offset by lower biopharmaceutical demand.
Bio-Techne Gears Up for Q1 Earnings Release: What's in the Cards?
by Zacks Equity Research
Within Spatial Biology, TECH is expected to have recorded strong growth, banking on the strong adoption of its new spatial biology instrument COMET.
TransMedics (TMDX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STE Gears Up for Q2 Earnings: Here's What You Need to Know
by Zacks Equity Research
STERIS' second-quarter fiscal 2025 results are likely to reflect the positives of normalizing the Healthcare backlog.
BIO Gears Up for Q3 Earnings: Here's What You Need to Know
by Zacks Equity Research
Within Bio-Rad's Life Science business, the ongoing weakness in the biotech and biopharma end markets might have severely affected sales.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Zimmer Biomet's third-quarter results are likely to reflect the strength in its three business segments, namely Hips, Knees and S.ET.
ALGN Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Align Technology's third-quarter results are likely to reflect the strength in its Clear Aligner and Systems & Services businesses.
Robust Analytical Instrument Segment Likely to Aid TMO's Q3 Earnings
by Zacks Equity Research
Strength in Analytical Instrument and Specialty Diagnostics segments is likely to have driven Thermo Fisher's third-quarter 2024 performance.
CAH Stock May Gain Following the Distribution Deal With T2 Biosystems
by Zacks Equity Research
Cardinal Health and T2 Biosystems announce an agreement selecting the former to sell direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens.
Integer Holdings (ITGR) Gains 30.5% YTD: What's Driving the Stock?
by Zacks Equity Research
Integer Holdings (ITGR) shares gain on the back of growth in the Medical segment. However, fluctuations in raw material prices and the oil and energy market are concerning.
BRKR Stock Might Gain From the Newly Launched OptoVolt Module
by Zacks Equity Research
At the Neuroscience 2024 conference, Bruker released its latest OptoVolt module, which seamlessly integrates with Ultima 2Pplus microscope and NeuraLight 3D SLM.